Cardinal Health officially opened the $11 million Center for the Advancement of Molecular Imaging —a new, collaborative laboratory that will seek to develop nuclear imaging agents that treat complex diseases like cancer, heart disease and neurological disorders —in Phoenix on July 18.
Dublin, Ohio-based Cardinal said its scientists, engineers and manufacturing experts will leverage the technology and infrastructure at a newly renovated and expanded 25,000-square-foot campus to help pharmaceutical companies and academic research institutions develop, test and commercialize new radiopharmaceuticals and PET imaging agents. They also will leverage the center for the manufacturing and dispensing process for imaging agents.
The center brings more than 20 new, high-technology jobs to Phoenix, including roles for radiochemists, engineers, scientists, product development managers, project managers and quality and regulatory personnel.
The center will house stand-alone laboratory space to allow the company’s partners—either academic researchers or industry partners—to conduct confidential radiopharmaceutical and PET biomarker experiments. It will also provide access to quality and regulatory expertise in order to earn FDA approval of new imaging agents; and will incorporate a global training facility for Cardinal Health’s Nuclear Pharmacy Services business.